Cross-Labeling Challenges Lack Easy Fix; Data Exclusivity Incentive Floated
This article was originally published in The Gray Sheet
Executive Summary
Data exclusivity extensions have been proposed as an incentive to encourage drug firms to amend product labeling in deference to related devices, but FDA and industry reps warn of complications inherent in this strategy